Lubiprostone: evaluation of the newest medication for the treatment of adult women with constipation-predominant irritable bowel syndrome

References

• ChangLHeitkemperMMGender differences in irritable bowel syndromeGastroenterology200212351686170112404243
   PubMed Web of Science ®Google Scholar
• BrandtLJCheyWDFoxx-OrensteinAEAn evidence-based systematic review on the management of irritable bowel syndromeAm J Gastroenterol2009104 Suppl 1S8S35
   Google Scholar
• LongstrethGFThompsonWGCheyWDHoughtonLAMearinFSpillerRCFunctional bowel disordersGastroenterology200613051480149116678561
   PubMed Web of Science ®Google Scholar
• DrossmanDLiZAndruzziEU.S, Householder survey of functional gastrointestinal disorders. Prevalence, sociodemography and health impactDig Dis Sci1993389156915808359066
   PubMed Web of Science ®Google Scholar
• ThompsonWGIrvineEJParePFerrazziSRanceLFunctional gastrointestinal disorders in Canada: first population based survey using Rome II criteria with suggestions for improving the questionnaireDig Dis Sci200247122523511837727
   PubMed Web of Science ®Google Scholar
• LeeOYMayerEASchmulsonMChangLNaliboffBGender- related differences in IBS symptomsAm J Gastroenterol20019672184219311467651
   PubMed Web of Science ®Google Scholar
• ChangLTonerBBFukodoSGender, age, society, culture, and the patient’s perspective in the functional gastrointestinal disordersGastroenterology200613051435144616678557
   PubMed Web of Science ®Google Scholar
• ChialHJCamilleriMGender differences in irritable bowel syndromeJ Gender Specif Med2002533745
   Google Scholar
• SandlerRSEpidemiology of irritable bowel syndrome in the United StatesGastroenterology19909924094152365191
   PubMed Web of Science ®Google Scholar
• ChangLReview article: epidemiology and quality of life in functional gastrointestinal disordersAliment Pharmacol Ther200420 Suppl 7S31S39
   PubMed Web of Science ®Google Scholar
• DrossmanDAWhiteheadWECamilleriMIrritable bowel syndrome: a technical review for practice guideline developmentGastroenterology19971126212021379178709
   PubMed Web of Science ®Google Scholar
• NyropKAPalssonOSLevyRLCosts of health care for irritable bowel syndrome, chronic constipation, functional diarrhea and functional abdominal painAliment Pharmacol Ther200726223724817593069
   PubMed Web of Science ®Google Scholar
• SchillerLRDennisETothGPrimary care physicians consider constipation as a severe and bothersome medical condition that negatively impacts patients’ lives [abstract 724]Am J Gastroenterol200499 SupplS234S235
   Google Scholar
• LemboAIrritable bowel syndrome medications side effects surveyJ Clin Gastroenterol200438977678115365404
   PubMed Web of Science ®Google Scholar
• LacyBELevyLCLubiprostone: a chloride channel activatorJ Clin Gastroenterol200741434535117413599
   PubMed Web of Science ®Google Scholar
• LacyBECheyWDLubiprostone: chronic constipation and irritable bowel with constipationExpert Opin Pharmacother200910114315219236188
   PubMed Web of Science ®Google Scholar
• BijveldsMJBotAGEscherJCDe JongeHRActivation of intestinal Cl- secretion by lubiprostone requires the cystic fibrosis transmembrane conductance regulatorGastroenterology2009137397698519454284
   PubMed Web of Science ®Google Scholar
• ChangLLacyBEQuigleyEMMSchoenfeldPSEmerging diagnostic and treatment strategies for irritable bowel syndromeGastroenterol Hepatol2008410122
   Google Scholar
• FrankLKleinmanLRentzACieslaGKimJJZackerCHealthrelated quality of life associated with irritable bowel syndrome: comparison with other chronic diseasesClin Ther2002244674689
   Web of Science ®Google Scholar
• JohansonJFDrossmanDAPanasRWahleAUenoRClinical trial clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipationAliment Pharmacol Ther200827868569618248656
   PubMed Web of Science ®Google Scholar
• KhoshooVArmsteadCLandryLEffect of a laxative with and without tegaserod in adolescents with constipation predominant irritable bowel syndromeAliment Pharmacol Ther200623119119616393297
   PubMed Web of Science ®Google Scholar
• LangLThe Food and Drug Administration approves lubiprostone for irritable bowel syndrome with constipationGastroenterology200813517
   Web of Science ®Google Scholar
• SchillerLRCamilleriMLubiprostone: viewpoints [comment]Drugs200666688088116706563
   PubMed Web of Science ®Google Scholar
• AMITIZA^® (lubiprostone) [package insert]Bethesda, MDSucampo Pharmaceuticals, Inc2009
   Google Scholar
• OrrKKLubiprostone: a novel chloride channel activator for the treatment of constipationFormulary2006413118129
   Google Scholar
• CamilleriMBharuchaAUenoREffect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory and motor functions in healthy volunteersAm J Physiol Gastrointest Liver Physiol20062905G942G94716603730
   PubMed Web of Science ®Google Scholar
• SweetserSBusciglioIACamillerMEffect of a chloride channel activator, lubiprostone, on colonic sensory and motor functions in healthy subjectsAm J Physiol Gastrointest Liver Physiol20092962G295G30119033530
   PubMed Web of Science ®Google Scholar
• LipeckaJBaliMThomasJDistribution of CCl-2 chloride channel in rat and human epithelial tissueAm J Physiol Cell Physiol20022824C805C81611880269
   PubMed Web of Science ®Google Scholar
• VandewalleAExpression and function of CLC and cystic fibrosis transmembrane conductance regulator chloride channels in renal epithelial tubule cells pathophysiological implicationsChang Gung Med J2007301172517477025
   PubMedGoogle Scholar
• CuppolettiJMalinowskaDHTewariKPSPI-0211 activates T84 cell chloride transport and recombinant human ClC-2 chloride currentsAm J Physiol Cell Physiol20042875C1173C118315213059
   PubMed Web of Science ®Google Scholar
• Lubiprostone: RU 0211, SPI 0211Drugs R D2005624524815991886
   PubMedGoogle Scholar
• GriderJRJinJGDistinct populations of sensory neurons mediate the peristaltic reflex elicited by muscle stretch and mucosal stimulationJ Neurosci199414Suppl 5(Pt 1)S2854S2860
   Web of Science ®Google Scholar
• CatalanMNiemeyerMICidLPBasolateral ClC-2 chloride channels in surface colon epithelium: regulation by a direct effect of intracellular chlorideGastroenterology200412641104111415057749
   PubMed Web of Science ®Google Scholar
• GyomoreyKYegerHAckerlyCExpression of the chloride channel ClC-2 in the murine small intestine epitheliumAm J Physiol Cell Physiol20002796C1787C179411078693
   PubMed Web of Science ®Google Scholar
• FritschJEdelmanAModulation of the hyperpolarization-activated Cl− current in human T84 epithelial cells by phosphorylationJ Physiol1996490Pt 11151288745282
   PubMed Web of Science ®Google Scholar
• BaoHFLiLSelfJA synthetic prostone activates apical chloride channels in A6 epithelial cellsAm J Physiol Gastrointest Liver Physiol20092952G234G25118511742
   PubMed Web of Science ®Google Scholar
• TewariKPMalinowskaDHSherryAMCuppolettiJPKA and arachidonic acid activation of human recombinant ClC-2 chloride channelsAm J Physiol Cell Physiol20002791C40C5010898715
   PubMed Web of Science ®Google Scholar
• FeiGWangYZLiuSStimulation of mucosal secretion by lubiprostone (SPI-0211) in guinea pig small intestine and colonAm J Physiol Gastrointest Liver Physiol20092964G823G83219179625
   PubMed Web of Science ®Google Scholar
• MizumoriMAkibaYKaunitzJDLupiprostone stimulates duodenal bicarbonate secretion in ratsDig Dis Sci200954102063206919657734
   PubMed Web of Science ®Google Scholar
• BassilAKBomanRAJarvieEMActivation of prostaglandin EP receptors by lubiprostone in rat and human stomach and colonBr J Pharmacol2008154112613518332851
   PubMed Web of Science ®Google Scholar
• CuppolettiJMalinowskDHChakrabartiJUenoREffects of lubiprostone on human uterine smooth muscle cellsProstaglandins Other Lipid Mediat2008861–4566018440264
   PubMed Web of Science ®Google Scholar
• RiveraEWahleAJoswickTRUenoRLubiprostone, a novel type-2 chloride channel (Clc-2) activator, does not affect serum electrolyte balance in elderly and non-elderly patients with chronic idiopathic constipationGastroenterology20071324 Suppl 2A191A192
   Web of Science ®Google Scholar
• SprengerCCopaAMorganrothJEffect of lubiprostone, a unique agent for the treatment of chronic idiopathic constipation on clinical electrocardiogram resultsGastroenterology20071324 Suppl 2A325
   Web of Science ®Google Scholar
• MacDonaldKDMcKenzieKRHendersonMJLubiprostone activates non-CFTR-dependent respiratory epithelial chloride secretion in cystic fibrosis MiceAm J Physiol Lung Cell Mol Physiol20082959L933L94018805957
   PubMed Web of Science ®Google Scholar
• JooNSWineJJCuthbertAWLubiprostone stimulates secretion from tracheal submucosal glands of sheep, pigs and humansAm J Physiol Lung Cell Mol Physiol20092965L811L82419233902
   PubMed Web of Science ®Google Scholar
• XiaoZLPricoloVBiancaniPBeharJRole of progesterone signaling in the Regulation of G-protein levels in female chronic constipationGastroenterology2005128366767515765402
   PubMed Web of Science ®Google Scholar
• WhiteheadWEHoltkotterBEnckPTolerance for rectosigmoid distention in irritable bowel syndromeGastroenterology1990984118711922323511
   PubMed Web of Science ®Google Scholar
• MunakataJNaliboffBHarrafFRepetitive sigmoid stimulation induces rectal hyperalgesia in patients with irritable bowel syndromeGastroenterology1997112155638978343
   PubMed Web of Science ®Google Scholar
• RagnarrssonGHallbookOBodemarGAbdominal symptoms are not related to anorectal function in the irritable bowel syndromeScand J Gastroenterol199934325025810232868
   PubMed Web of Science ®Google Scholar
• ChangLMayerEALabusJEffect of sex on perception of rectosigmoid stimuli in irritable bowel syndromeAm J Physiol Regul Integr Comp Physiol2006292R277R28416574882
   PubMed Web of Science ®Google Scholar
• HoughtonLALeaRJacksonNWhorwellPUThe menstrual cycle affects rectal sensitivity in patients with irritable bowel syndrome but not healthy volunteersGut200250447147411889064
   PubMed Web of Science ®Google Scholar
• BermanSMunakataJNaliboffBDGender differences in regional brain response to visceral pressure in IBS patientsEur J Pain20004215717210957697
   PubMed Web of Science ®Google Scholar
• NaliboffBDBermanSChangLSex-related differences in IBS patients:central processing of visceral stimuliGastroenterology200312471738174712806606
   PubMed Web of Science ®Google Scholar
• CamilleriMMayerEADrossmanDAImprovement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonistAliment Pharmacol Ther19991391149115910468696
   PubMed Web of Science ®Google Scholar
• ChangLAmeenVZDukesGEMcSorleyDMayerEAA dose-ranging, phase II study of the efficacy and safety of alosetron hydrochloride (Lotronex) in men with diarrhea-predominant IBSAm J Gastroenterol2005100111512315654790
   PubMed Web of Science ®Google Scholar
• BradetteMMoennikesHCarterFCilansetron in irritable bowel syndrome with diarrhea predominance (IBS-D). Efficacy and safety in a 6 month studyGastroenterology20041264 Suppl 2A42
   Google Scholar
• CoremnansGClouseRECarterFKrauseGCarasSSteinbormCCilansetron, a novel 5-HT3 antagonist, demonstrated efficacy in males with irritable bowel syndrome with diarrhea predominance (IBS-D)Gastroenterology20041264 Suppl 2A643
   Web of Science ®Google Scholar
• Muller-LissnerSAFumagalliIBardhanKDTegaserod, a 5HT (4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipationAliment Pharmacol Ther200115101655166611564007
   PubMed Web of Science ®Google Scholar
• KellowJLeeOYChangFYAn Asia-Pacific, double-blind, placebo controlled randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndromeGut200352567167612692051
   PubMed Web of Science ®Google Scholar
• CamilleriMAtanasovaECarlsonPJSerotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndromeGastroenterology2002123242543212145795
   PubMed Web of Science ®Google Scholar
• JohansonJFGarganoMAPatchenMLUenoREfficacy and safety of a novel compound, RU-0211, for the treatment of constipationGastroenterology20021221 Suppl 4A315
   Web of Science ®Google Scholar
• JohansonJFGarganoMAPatchenMLUenoRPhase III efficacy and safety of RU-0211, a novel chloride channel activator, for the treatment of constipationGastroenterology20031244 Suppl 1A48
   Web of Science ®Google Scholar
• JohansonJFGarganoMAPatchenMLUenoRPhase III study of lubiprostone, a chloride channel-2 (CIC-2) activator for treatment of constipation: Safety and primary efficacyAm J Gastroenterol20051009 Suppl 9sS328
   Web of Science ®Google Scholar
• JohansonJFUenoRLubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safetyAliment Pharmacol Ther200725111351136117509103
   PubMed Web of Science ®Google Scholar
• BarishCFDrossmanDJohansonJFUenoREfficacy and safety of lubiprostone in chronic constipationDig Dis Sci20105541090109720012484
   PubMed Web of Science ®Google Scholar
• JohansonJFMortonDGeenenJUenoRMulti-center, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator in patients with chronic constipationAm J Gastroenterol2008103117017717916109
   PubMed Web of Science ®Google Scholar
• ThompsonWGLongstrethGDrossmanDAHeatonKIrvineEJMuller-LissnerSDrossmanDACorazziariETalleyNJThompsonWGWhiteheadWEFunctional bowel disorders and functional abdominal painRome II: The Functional Gastrointestinal DisordersMcLean VADagnon Associates, Inc2000351432
   Google Scholar
• AnonymousLubiprostone (amitiza) for chronic constipationMed Lett Drugs Ther2006481236474816770297
   PubMed Web of Science ®Google Scholar
• JohansonJFGarganoMAHollandPCPatchenMLUenoRPhase III efficacy and safety of RU-0211, a novel chloride channel activator, for the treatment of constipationGastroenterology20031244 Suppl 1A104
   Web of Science ®Google Scholar
• UenoRPanasRWahleAZhuYHollandPCLong-term safety and efficacy of lubiprostone for the treatment of chronic constipation in elderly subjectsGastroenterology20061304 Suppl 2A188
   Web of Science ®Google Scholar
• JohansonJFGarganoMAPatchenMLUenoRMulti-center open label study of lubiprostone for the treatment of chronic constipationAm J Gastroenterol20051009 Suppl 9S331
   Web of Science ®Google Scholar
• JohansonJFGarganoMAPatchenMLUenoRPhase III, randomized withdrawal study of RU-0211, a novel chloride channel activator for the treatment of constipationGastroenterology20041264 Suppl 2S100
   Web of Science ®Google Scholar
• CheyWDSaadRJPanasRWahleAUenoRDiscontinuation of lubiprostone treatment for irritable bowel syndrome with constipation is not associated with symptom increase or recurrence: results from a randomized withdrawal studyGastroenterology20081344 Suppl 1A401
   Web of Science ®Google Scholar
• DrossmanDACheyWDJohansonJFClinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome – results of two randomized, placebo-controlled studiesAliment Pharmacol Ther200929332934119006537
   PubMed Web of Science ®Google Scholar
• DrossmanDACheyWDScottCPanasRUenoRHealth-related quality of life in adults with irritable bowel syndrome with constipation: results of combined analysis of two phase 3 studies with lubiprostoneGastroenterology20081344 Suppl 1A469
   Google Scholar
• CheyWDDrossmanDAScottCPanasRUenoRWhat symptoms drive global symptom improvement with lubiprostone in patients with irritable bowel syndrome and constipation: data from two multicenter, randomized, placebo-controlled trialsGastroenterology20081344 Suppl 1A28
   Web of Science ®Google Scholar
• CamilleriMGormanHIntestinal permeability and IBSNeurogastroenterol Motil200719754555217593135
   PubMed Web of Science ®Google Scholar
• DunlopSPHepbenJCampbellEAbnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromeAm J Gastroenterol200610161288120416771951
   PubMed Web of Science ®Google Scholar
• MarshallJKThabaneMGargAXClarkWMedingsJCollinsSMIntestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, OntarioAliment Pharmacol Ther20042011–121317132215606393
   PubMed Web of Science ®Google Scholar
• SpillerRCJenkinsDThornleyJPIncreased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndromeGut200047580481111076879
   PubMed Web of Science ®Google Scholar
• CrowellMDHarrisLALunsfordTNDiBaiseJEmerging drugs for chronic constipationExpert Opin Emerg Drugs200914349350419650747
   PubMed Web of Science ®Google Scholar
• CamilleriMReview article: new receptor targets for medical therapy in irritable bowel syndromeAliment Pharmacol Ther2010311354619785622
   PubMed Web of Science ®Google Scholar
• CamilleriMKerstensRBeyensGRobinsonPVandeplasscheLA double-blind, placebo controlled trial to evaluate the safety and tolerability of prucalo-pride oral solution in constipated elderly patients living in a nursing facilityGastroenterology2009136 Suppl 1S240
   Google Scholar
• CamilleriMBeyensGKertsensRVandeplasscheLLong-term follow up of safety and satisfaction with bowel function in response to oral prucalopride in patients with chronic constipationGastroenterology2009136 Suppl 1S160
   Google Scholar
• ForteLRJrUroguanylin and guanylin peptides: pharmacology and experimental and therapeuticsPharmacol Ther2004104213716215518884
   PubMed Web of Science ®Google Scholar
• LemboAJKurtzCBMacdougallJEEfficacy of linaclotide for patients with chronic constipationGastroenterology2010138388689520045700
   PubMed Web of Science ®Google Scholar
• DrossmanDAMorrisCBSchneckSInternational survey of patients with IBS: symptom features and their severity, health status treatments, and risk taking to achieve clinical benefitJ Clin Gastroenterol200943654155019384249
   PubMed Web of Science ®Google Scholar
• DrossmanDAThompsonWGThe irritable bowel syndrome: review and a graduated multicomponent treatment approachAnn Intern Med199211612 Pt 1100910161586090
   PubMed Web of Science ®Google Scholar
• SpiegelBHarrisLALucakSDeveloping valid and reliable health utilities in irritable bowel syndrome: results from the IBS PROOF cohortAm J Gastroenterol200910481984199119491835
   PubMed Web of Science ®Google Scholar
• SpiegelBStricklandANaliboffBDMayerEAChangLPredictors of patient-assessed illness severity in irritable bowel syndromeAm J Gastroenterol2008103102536254318637089
   PubMed Web of Science ®Google Scholar